Controlled-release biocompatible ocular drug delivery implant devices and methods

• US 6,331,313 B1
• Filed: 10/22/1999
• Issued: 12/18/2001
• Est. Priority Date: 10/22/1999
• Status: Expired due to Term

• Current Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Original Assignee: Oculex Pharmaceuticals, Inc. (Abbvie Incorporated)
• Inventors: Berger, Donald E. Jr., Wong, Vernon G., Hu, Mae W. L.
• Primary Examiner(s): Page, Thurman K.
• Assistant Examiner(s): DI NOLA BARON, LILIANA
• Application Number:
  US09/426,141
• Time in Patent Office: 788 Days
• Field of Search: 424/428, 424/422, 424/427, 424/424, 424/423, 604/891.1
• US Class Current: 424/427
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61P 27/02 Ophthalmic agents

Abstract

Controlled release devices are disclosed which are biocompatible and can be implanted into the eye. The devices have a core comprising a drug and a polymeric outer layer which is substantially impermeable to the entrance of an environmental fluid and substantially impermeable to the release of the drug during a delivery period, and drug release is effected through an orifice in the outer layer. These devices have an orifice area of less than 10% of the total surface area of the device and can be used to deliver a variety of drugs with varying degrees of solubility and or molecular weight. Methods are also provided for using these drug delivery devices.

Claims

1. A biocompatible implantable ocular controlled release drug delivery device sized for implantation within an eye for continuously delivering a drug within the eye for a period of at least several weeks comprising a polymeric outer layer that is substantially impermeable to the drug and ocular fluids covering a core comprising a drug that dissolves in ocular fluids, wherein said outer layer has one or more orifices through which ocular fluids may pass to contact the core and dissolve drug and dissolved drug may pass to the exterior of the device, said orifices in total having an area less than one percent of the total surface area of said device, and wherein the rate of release of the drug is determined solely by the composition of the core and the total surface area of the one or more orifices relative to the total surface area of said device.

2. The device of claim 1, wherein said orifices have circular openings with diameters in the range of about 0.001 mm to 0.5 mm.

3. The device of claim 1, wherein said device is cylindrical and has a diameter of about 0.5 and 4 mm and a length of about 3 to 7 mm.

4. The device of claim 1, wherein said outer layer comprises polytetrafluoroethylene, polyfluorinated ethylenepropylene, polylactic acid, polyglycolic acid, or silicone or a mixture thereof.

5. The device of claim 1, wherein said drug is an antibiotic, an antiviral agent, an antifingal agent, an anticancer agent, an antiglaucoma agent, an antiinflammatory agent, an analgesic, an immunomodulatory agent, a macromolecule or a mixture thereof.

6. The device of claim 5, wherein said drug is an antiviral agent that is effective against a cytomegalovirus, a herpes virus, an adenovirus, or a mixture thereof.

7. The device of claim 5, wherein said drug is a cyclosporin, tacrolimus, an interferon, or a mixture thereof.

8. The device of claim 5, wherein said drug is a nucleic acid, a protein, a carbohydrate, a glycoprotein, a lipid, a glycolipid, or a mixture thereof.

9. The device of claim 5, wherein the drug is gentamicin, cefazolin, dexamethasone, aldose reductase inhibitor, ganciclovir, fluocinolone, triamcinolone, fluorometholone, prednisone, prednisolone or a mixture thereof.

10. The device of claim 1, wherein the outer layer is biodegradable.

11. The device of claim 1, wherein the core consists essentially of the drug.

12. The drug delivery device of claim 1, wherein the substantially impermeable outer layer comprises polytetrafluoroethylene, and said drug is gentamicin, cefazolin, or a mixture thereof.

13. The drug delivery device of claim 1, wherein the substantially impermeable outer layer comprises polyfluorinated ethylenepropylene, and said drug is dexamethasone.

14. The drug delivery device of claim 1, wherein the substantially impermeable outer layer comprises polytetrafluoroethylene, and said drug is an aldose reductase inhibitor.

15. The drug delivery device of claim 1, wherein the substantially impermeable outer layer comprises polytetrafluoroethylene, and said drug is 9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]-methyl]-guanine.

16. The drug delivery device of claim 1, wherein the substantially impermeable outer layer comprises polytetrafluoroethylene or silicone or a mixture thereof, and said drug is ganciclovir.

17. The drug delivery device of claim 10, wherein the substantially impermeable biodegradable outer layer comprises polylactic acid, polyglycolic acid, or a mixture thereof, and said drug is ganciclovir.

18. A method of treating or preventing an ocular condition in an eye comprising implanting a biocompatible ocular controlled release drug delivery device of claim 1 within the eye.

19. The device of claim 1, wherein said outer layer has two or more orifices.